22.03USD-4.07%Mkt Cap: 788.62M USDP/E: —Last update: 2026-06-01
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap788.62M USD
Enterprise Value634.36M USD
Revenue (TTM)10.00M USD
Gross Profit10.00M USD
Net Income (TTM)-68.87M USD
Revenue/Share0.7060 USD
Last Price22.03 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees48
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.97
PEG—
EV/EBITDA-7.16
EV/Revenue63.44
P/S83.67
P/B2.75
EPS (TTM)-2.11
EPS (Forward)-3.33
52W Range
13.8842% of range33.20
52W High33.20 USD
52W Low13.88 USD
Profitability
Gross Margin100.00%
Oper. Margin-899.93%
EBITDA Margin0.00%
Profit Margin-529.77%
ROE-33.50%
ROA-30.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-76.44M USD
CapEx (TTM)235.00K USD
FCF Margin-575.26%
FCF Yield-7.29%
Net Debt-202.35M USD
Net Debt/EBITDA2.28
Balance Sheet
Debt/Equity0.01
Current Ratio20.36
Quick Ratio19.94
Book Value/Sh8.456 USD
Cash/Share5.871 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)52.25 USD
Target Range50.00 USD – 55.00 USD
# Analysts8
Ownership
Shares Out.36.02M
Float19.96M
Insiders7.98%
Institutions110.47%
Short Interest
Short Ratio9.3d
Short % Float12.78%
Short % Out.8.60%
Shares Short3.10M
Short (prev mo.)3.46M
Technical
SMA 5024.22 (-9.0%)
SMA 20022.13 (-0.4%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)342.02K
Avg Vol (10d)437.03K
Technical Indicators
RSI (14)46.9
MACD-0.4128
MACD Signal-0.5410
MACD Hist.+0.1282
BB Upper24.65 USD
BB Middle23.07 USD
BB Lower21.50 USD
BB Width13.64%
ATR (14)1.514 USD
Vol Ratio (20d)0.23x